Breaking Finance News

Sarepta Therapeutics Inc (NASDAQ:SRPT) has been upgraded to Buy in a statement by Janney Montgomery Scott earlier today.

Having a price of $51.30, Sarepta Therapeutics Inc (NASDAQ:SRPT) traded 91.30% higher on the day. With the last stock close up 163.13% relative to the two hundred day moving average, compared to the Standard & Poor’s 500 Index which has decreased -0.01% over the date range. SRPT has been tracking to a 50-day average of $26.16 and two hundred day average of $20.47. Volume of trade was was up over the average, with 29,541,278 shares of SRPT changing hands over the typical 2,328,380 shares.

Janney Montgomery Scott has upgraded Sarepta Therapeutics Inc(NASDAQ:SRPT) to Buy in a statement released 9/19/2016.

Previously on 7/22/2016, Needham reported on Sarepta Therapeutics Inc(NASDAQ:SRPT) raised the target price from $20.00 to $26.00. At the time, this indicated a possible upside of 0.15%.

Recent Performance Chart:

Sarepta Therapeutics Inc (NASDAQ:SRPT)

In addition to Janney Montgomery Scott reporting it’s price target, a total of 13 brokerages have released a report on the company. The 12-month target price is $20.77 with three firms rating the stock a strong buy, one analyst rating the stock a buy, five analysts rating the stock a hold, four brokerages rating the stock to underperform, and lastly one brokerage rating the stock as sell.

Sarepta Therapeutics Inc has a 52 week low of $8.00 and a 52 week high of $56.18 and has a market capitalization of $0.0.

About Sarepta Therapeutics Inc (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company’s lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, and is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *